1. Gleich GJ, Loegering DA. Immunobiology of eosinophils. Annu Rev Immunol. 1984. 2:429–459.

2. Rothenberg ME. Eosinophilia. N Engl J Med. 1998. 338:1592–1600.

3. Weller PF. Eosinophils: structure and functions. Curr Opin Immunol. 1994. 6:85–90.

4. Gleich GJ, Adolphson CR. The eosinophilic leukocyte: structure and function. Adv Immunol. 1986. 39:177–253.

5. Kita H. The eosinophil: a cytokine-producing cell? J Allergy Clin Immunol. 1996. 97:889–892.

6. Shi HZ. Eosinophils function as antigen-presenting cells. J Leukoc Biol. 2004. 76:520–527.

7. Shi HZ, Humbles A, Gerard C, Jin Z, Weller PF. Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest. 2000. 105:945–953.

8. Steinbach KH, Schick P, Trepel F, Raffler H, Dohrmann J, Heilgeist G, et al. Estimation of kinetic parameters of neutrophilic, eosinophilic, and basophilic granulocytes in human blood. Blut. 1979. 39:27–38.

9. Newman TM, Tian M, Gomperts BD. Ultrastructural characterization of tannic acid-arrested degranulation of permeabilized guinea pig eosinophils stimulated with GTP-gamma-S. Eur J Cell Biol. 1996. 70:209–220.

10. Kobayashi H. Effect of c-kit ligand (stem cell factor) in combination with interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3, on eosinophil lineage. Int J Hematol. 1993. 58:21–26.

11. Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood. 1989. 73:1504–1512.

12. Palframan RT, Collins PD, Severs NJ, Rothery S, Williams TJ, Rankin SM. Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin 5: the role of specific adhesion molecules and phosphatidylinositol 3-kinase. J Exp Med. 1998. 188:1621–1632.

13. Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity. 1996. 4:15–24.

14. McNagny K, Graf T. Making eosinophils through subtle shifts in transcription factor expression. J Exp Med. 2002. 195:F43–F47.

15. Nerlov C, Graf T. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev. 1998. 12:2403–2412.

16. Nerlov C, McNagny KM, Doderlein G, Kowenz-Leutz E, Graf T. Distinct C/EBP functions are required for eosinophil lineage commitment and maturation. Genes Dev. 1998. 12:2413–2423.

17. Yu C, Cantor AB, Yang H, Browne C, Wells RA, Fujiwara Y, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med. 2002. 195:1387–1395.

18. Hirasawa R, Shimizu R, Takahashi S, Osawa M, Takayanagi S, Kato Y, et al. Essential and instructive roles of GATA factors in eosinophil development. J Exp Med. 2002. 195:1379–1386.

19. Du J, Stankiewicz MJ, Liu Y, Xi Q, Schmitz JE, Lekstrom-Himes JA, et al. Novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein. J Biol Chem. 2002. 277:43481–43494.

20. Kita H, Abu-Ghazaleh RI, Sur S, Gleich GJ. Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. J Immunol. 1995. 154:4749–4758.

21. Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature. 1986. 321:613–616.

22. Wasmoen TL, Bell MP, Loegering DA, Gleich GJ, Prendergast FG, McKean DJ. Biochemical and amino acid sequence analysis of human eosinophil granule major basic protein. J Biol Chem. 1988. 263:12559–12563.

23. Nittoh T, Hirakata M, Mue S, Ohuchi K. Identification of cDNA encoding rat eosinophil cationic protein/eosinophil-associated ribonuclease. Biochim Biophys Acta. 1997. 1351:42–46.

24. Tai PC, Spry CJ, Peterson C, Venge P, Olsson I. Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature. 1984. 309:182–184.

25. Fredens K, Dahl R, Venge P. The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X. J Allergy Clin Immunol. 1982. 70:361–366.

26. Rosenberg HF, Tenen DG, Ackerman SJ. Molecular cloning of the human eosinophil-derived neurotoxin: a member of the ribonuclease gene family. Proc Natl Acad Sci U S A. 1989. 86:4460–4464.

27. Ten RM, Butterfield JH, Kita H, Weiler DA, Fischkoff S, Ishizaka T, et al. Eosinophil differentiation of human umbilical cord mononuclear cells and prolonged survival of mature eosinophils by murine EL-4 thymoma cell conditioned medium. Cytokine. 1991. 3:350–359.

28. Rizo J, Sudhof TC. Snares and Munc18 in synaptic vesicle fusion. Nat Rev Neurosci. 2002. 3:641–653.

29. Bochner BS, Schleimer RP. The role of adhesion molecules in human eosinophil and basophil recruitment. J Allergy Clin Immunol. 1994. 94:427–438.

30. Zimmermann N, Hershey GK, Foster PS, Rothenberg ME. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol. 2003. 111:227–242.

31. Zhu Z, Zheng T, Homer RJ, Kim YK, Chen NY, Cohn L, et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science. 2004. 304:1678–1682.

32. Mawhorter SD, Kazura JW, Boom WH. Human eosinophils as antigen-presenting cells: relative efficiency for superantigen- and antigen-induced CD4+ T-cell proliferation. Immunology. 1994. 81:584–591.

33. Handzel ZT, Busse WW, Sedgwick JB, Vrtis R, Lee WM, Kelly EA, et al. Eosinophils bind rhinovirus and activate virus-specific T cells. J Immunol. 1998. 160:1279–1284.

34. MacKenzie JR, Mattes J, Dent LA, Foster PS. Eosinophils promote allergic disease of the lung by regulating CD4(+) Th2 lymphocyte function. J Immunol. 2001. 167:3146–3155.

35. Lacy P, Moqbel R. Eosinophil cytokines. Chem Immunol. 2000. 76:134–155.

36. Piliponsky AM, Gleich GJ, Bar I, Levi-Schaffer F. Effects of eosinophils on mast cells: a new pathway for the perpetuation of allergic inflammation. Mol Immunol. 2002. 38:1369.

37. Solomon A, Aloe L, Pe'er J, Frucht-Pery J, Bonini S, Bonini S, et al. Nerve growth factor is preformed in and activates human peripheral blood eosinophils. J Allergy Clin Immunol. 1998. 102:454–460.

38. Bullock ED, Johnson EM Jr. Nerve growth factor induces the expression of certain cytokine genes and bcl-2 in mast cells. Potential role in survival promotion. J Biol Chem. 1996. 271:27500–27508.

39. Horigome K, Bullock ED, Johnson EM Jr. Effects of nerve growth factor on rat peritoneal mast cells. Survival promotion and immediate-early gene induction. J Biol Chem. 1994. 269:2695–2702.

40. Williams TJ. The eosinophil enigma. J Clin Invest. 2004. 113:507–509.

41. Kwak YG, Song CH, Yi HK, Hwang PH, Kim JS, Lee KS, et al. Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Invest. 2003. 111:1083–1092.

42. Kim SR, Lee KS, Park SJ, Min KH, Lee KY, Choe YH, et al. PTEN down-regulates IL-17 expression in a murine model of toluene diisocyanate-induced airway disease. J Immunol. 2007. 179:6820–6829.